Galapagos NV (Galapagos) is a biotechnology company that discovers and develops small-molecule medicines for the treatment of inflammatory and fibrotic diseases. It offers Filgotinib medication targeting rheumatoid arthritis (RA). The company is investigating the GLPG3667 compound against autoimmune indications. The company offers its products in the therapeutic areas of immunology and oncology. It partners with academic organizations and universities to accelerate development and boost innovation in discovery, preclinical and clinical development. The company operates in Belgium, the Netherlands, France, Germany, Austria, Italy, Spain, the Nordics, Switzerland, the UK and the US. Galapagos is headquartered in Mechelen, Belgium.
Headquarters
Belgium
Address
Generaal De Wittelaan L11 A3, Malines (Mechelen), 2800
Website
www.glpg.com
Telephone
32 15 342900
No of Employees
1,233
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
GLPG (AMS)
Revenue (2022)
$580.6M
2.5%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-111.2%
(2022 vs 2021)
Market Cap*
$2.6B
Net Profit Margin (2022)
XYZ
-106.0%
(2022 vs 2021)
* As of and is in US$
Galapagos NV premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Filgotinib |
| 3667 |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In November, the company entered into an agreement with miDiagnostics under which miDiagnostics will develop an ultra-rapid chip-based point-of-care PCR sterility testing method for use with the company’s decentralized CAR-T CellPoint manufacturing platform. |
| 2023 | Contracts/Agreements | In November, the company entered into a partnership with Landmark Bio, under the partnership, Landmark Bio will perform GMP manufacturing of clinical trial batches of Galapagos' development programs of chimeric antigen receptor T-cell therapies in hematology-oncology. |
| 2023 | Contracts/Agreements | In October, the company signed a letter of intent to transfer Jyseleca business to Alfasigma. |
Competitor Comparison
| Key Parameters | Galapagos NV | Mithra Pharmaceuticals SA | TherapeuticsMD Inc | Oxurion NV | Ablynx NV |
|---|---|---|---|---|---|
| Headquarters | Belgium | Belgium | United States of America | Belgium | Belgium |
| City | Malines (Mechelen) | Liege | Boca Raton | Leuven (Louvain) | Ghent |
| State/Province | - | Liege | Florida | - | Flandre Orientale |
| No. of Employees | 1,233 | 229 | 1 | 27 | 450 |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Paul Stoffels | Chairman; Chief Executive Officer | Executive Board | 2022 | - |
| Thad Huston | Chief Financial Officer; Chief Operating Officer | Senior Management | 2023 | - |
| Philippe Alen | Senior Vice President; Head - Business Development | Senior Management | 2022 | - |
| Michele Manto | Chief Commercial Officer | Senior Management | 2020 | - |
| Valeria Cnossen | General Counsel | Senior Management | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward